GILD · News · 20260824N

Revenue Performance and Mix

GILEAD SCIENCES, INC. · 2026-08-24 · Importance 37 · Surprise 6

Gilead Sciences reported second-quarter revenue of approximately $7.80 billion. The quarterly revenue exceeded analyst estimates, representing a material revenue figure relative to the company’s stated revenue base. The digest does not provide a YoY or sequential revenue comparison or a product-level mix breakdown.

Key facts

• 83.67% of Gilead Sciences' stock is owned by institutional investors and hedge funds. source
• An investment of $1000 in Gilead Sciences five years ago would now be worth $2,054.32, an annualized return of 15.54%. source
• Cibc World Market Inc. acquired a new stake of 338,002 shares in Gilead Sciences, Inc., valued at approximately $42.703 million. source
• Sanctuary Advisors LLC acquired 203,044 shares of Gilead Sciences, Inc. during the second quarter, a stake valued at approximately $25.65 million. source
• Meiji Yasuda Asset Management Co Ltd acquired a new stake of 33,417 shares in Gilead Sciences, Inc., valued at approximately $4.22 million. source
• Te Ahumairangi Investment Management Ltd purchased 48,936 shares of Gilead Sciences, Inc. in the second quarter, a $6.18 million investment. source
• Osmosis Investment Management UK Ltd acquired 90,311 shares of Gilead Sciences, Inc. valued at approximately $11.41 million during the second quarter. source